Organized by Biocentury and the EBD Group, the BIO-Equity 2021 event attracts leading innovative pharma and biotech companies as well as specialized investors in life sciences. The event enables the exchange of the latest advances in biotechnology and offers a strong partnering platform to foster value-creating collaborations.
Raúl Insa, CEO of SOM Biotech highlights: “We look forward to attending the BIO-Equity 2021 event, to continue building a strong network of business partners and investors. Both are essential pillars of our growth strategy. This event is a great opportunity to give an update on our latest pipeline developments and to showcase the great potential of our proprietary AI-based drug discovery platform. SOMAIPRO is a pioneering approach that has enabled us to build a robust drug development pipeline for orphan/CNS drug candidates with strong blockbuster potential. It is a powerful tool, a drug discovery engine that will continue to help us and our business partners to foster drug development and provide new treatments to tackle acute medical needs safely and with efficacy”.